Pharmacogenetic allele frequencies study
Ended Definitive Contract Awarded Last action
- Contract number
- 75D30123C16750
- Awardee
-
Rprd Diagnostics, LLC UEI KNJ1H1EC8KF5
- Awarding agency
-
CDC Pittsburgh
Centers for Disease Control and Prevention, Department of Health and Human Services
- Obligated
- $520,661
Award facts
- Opportunity
-
- 75D30123R72718 Solicitation number
- Contract value 100% obligated
- $520,661.01 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 621511 Medical Laboratories
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Time and Materials
- Place of performance
- Wauwatosa, WI 53226, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Centers for Disease Control and Prevention (CDC) awarded a $520,661 definitive contract to Rprd Diagnostics, LLC Rprdx Division to conduct a Pharmacogenetic Allele Frequencies Study. The prime contractor will perform the study in Milwaukee, Wisconsin from September 1, 2023 through August 31, 2025. The contract utilizes a time and materials pricing structure. No subcontractors were identified.
Quick answers
Who was awarded contract 75D30123C16750?
75D30123C16750 was awarded to Rprd Diagnostics, LLC by CDC Pittsburgh (Centers for Disease Control and Prevention) on September 1, 2023.
How much is contract 75D30123C16750 worth?
The government has obligated $520,661 on 75D30123C16750.
Was contract 75D30123C16750 competed?
The extent of competition for 75D30123C16750 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award